Eight Roads Ventures
Eight Roads Ventures is a global venture capital firm partnering with technology and healthcare founders, operating teams across Asia, Europe, Israel, and the US.
Funder analysis
Web-researched analysis· v7What they fund
- Series B/C Scale-ups — $10M-$30M average cheque size for European and Israeli scale-ups, targeting 15-20 companies per fund. [2][3], - Enterprise & Consumer Tech — Companies with product-market fit seeking to scale sales, marketing, and international expansion. [3], - Fintech & Healthtech — Regulated industries with disruption potential, such as challenger banks and digital health platforms. [3], - Global Expansion — Companies looking to expand from Europe/Israel to the US, Asia, or globally, leveraging Eight Roads' network. [3]
Investment thesis
Eight Roads Ventures partners with ambitious technology and healthcare founders globally, leveraging a near 50-year history and a $5Bn+ AUM platform to support companies from early stages through growth. [1]
- Global Ecosystem Access — Provides entrepreneurs with access to a global ecosystem to leverage and learn from, connecting them with partners across Asia, Europe, Israel, and the US. [1]
- Fidelity Backing — The firm's backing by Fidelity allows it to be more focused and flexible when supporting portfolio companies, enabling long-term partnerships with ambitious founders. [1]
- Scale-up Focus — The firm targets scale-up companies, helping founders take their companies from 50 to 500 employees and beyond, with a focus on enterprise, consumer, fintech, and healthcare IT sectors. [2][3]
Value add
Eight Roads provides a global platform of operators to help founders scale, focusing on sales, marketing, international expansion, and management layer building. [3]
Fit verdict: Ideal for scale-ups in Europe/Israel/Asia seeking growth capital and global expansion support, particularly in enterprise, consumer, fintech, and healthtech.
Founder diligence script:
- How does Eight Roads' global network specifically help us enter [Target Market]?
- What is the typical timeline from term sheet to deployment for a Series B/C round?
- Can you share examples of portfolio companies that successfully scaled from 50 to 500 employees with your support?
- How do you structure follow-on investments for Series C and beyond?
Portfolio focus
- Enterprise SaaS — AppsFlyer (attribution platform), Icertis (contract intelligence), Neo4j (graph database). [1], - Consumer & D2C — Paidy (fintech in Japan), OZiva (plant-based nutrition in India), Treatwell (beauty booking). [1][4], - Healthcare & Healthtech — Oviva (digital health), Interactio (remote interpretation platform). [5][6], - Fintech — Compte Nickel (French neobank), Spendesk (spend management). [2][6]
Notable investments & exits
- AppsFlyer — IPO in 2022. [1], - Made.com — Acquired by Wayfair in 2019. [2], - Neo4j — Still private as of 2024. [1], - Treatwell — Acquired by Aena in 2021. [2], - Wallapop — Acquired by eBay in 2022. [2]
Strategic implications
Eight Roads' Fidelity backing provides a significant advantage in deploying large cheques ($10M-$30M) and offering long-term capital, which is rare for European scale-ups. The firm's focus on 'resource gaps' in scaling (sales, marketing, management) positions it as a strategic partner rather than just a capital provider, which could attract founders seeking operational support. The risk lies in the firm's ability to consistently find 'ambitious entrepreneurs' across a 'scattered' geography like Europe and Israel, which may lead to higher sourcing costs or missed opportunities in non-traditional hubs.
Where they could go further
Eight Roads could deepen its focus on AI-native companies in enterprise and healthcare, a sector seeing rapid growth and capital influx., The firm could establish a dedicated seed fund to capture earlier-stage deals in Europe and Israel, creating a pipeline for its growth fund., Eight Roads could enhance its value-add by creating a formalized 'scaling academy' for portfolio CEOs, leveraging its operator network., The firm could explore co-investment opportunities with Asian VCs to facilitate cross-border expansion for European/Israeli portfolio companies.